Ozmosi | Lorvotuzumab mertansine Drug Profile

Product Description

Mechanisms of Action: CD56 Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Small Cell Lung Cancer|Ovarian Cancer|Carcinoma, Merkel Cell|Multiple Myeloma

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00991562	IMGN0005	P1	Completed	Multiple Myeloma	2013-08-01	2019-03-19	Treatments
NCT00346385	CDR0000491231	P1	Completed	Small Cell Lung Cancer\|Carcinoma, Merkel Cell\|Ovarian Cancer	2011-10-01	2019-03-21	Treatments
NCT00346255	IMGN901	P1	Completed	Multiple Myeloma	2011-03-01	2025-08-27	Primary Endpoints\|Treatments
NCT02452554	ADVL1522	P2	Completed	Neurofibrosarcoma\|Rhabdomyosarcoma\|Synovial Sarcoma\|Wilms Tumor\|Neuroblastoma\|Pulmonary Blastoma	2017-06-30	2022-01-14	Primary Endpoints
NCT02420873	NCI-2015-00683	P2	Completed	Leukemia	2017-06-06	2019-03-20	Treatments
2010-022950-17	2010-022950-17	P2	Completed	Small Cell Lung Cancer	2015-05-12	2022-03-13	Treatments
NCT01237678	Immunogen 0007	P2	Terminated	Small Cell Lung Cancer	2015-05-01	2024-11-27	Primary Endpoints\|Treatments
NCT00065429	C10/IVB/001	P2	Completed	Small Cell Lung Cancer	2008-11-01	2019-03-21	Treatments

Recent News Events

Date	Type	Title
09/13/2023	News Article	NK Cells market size is expected to expand at a 11.7% CAGR forecasted from 2023 - 2030
09/13/2023	News Article	The K Cells market study's evaluation of the 5.3% CAGR forecasted for the K Cells industry from 2023 to 2030 helps identify growth opportunities and challenges.
01/01/2022	PubMed	Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
12/15/2020	PubMed	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Lorvotuzumab mertansine

Alternative Names: lorvotuzumab mertansine, bb-10901, imgn901 Clinical Status: Inactive Latest Update: 2023-09-13 Latest Update Note: News Article